Alembic Pharma’s revenue missed our estimate due to lower-than-expected revenue in the Ex-USA segment and lower-than-expected revenue in the API segment. We believe the Company will aim to maintain a growth trajectory in the US with new product launches while continuing to outperform the Indian Pharmaceutical Market in the long term.